Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07, Zacks reports. The business had revenue of $0.03 million during the quarter.
Enliven Therapeutics Stock Performance
NASDAQ:ELVN traded up $0.30 during trading hours on Monday, hitting $21.04. 140,000 shares of the company's stock traded hands, compared to its average volume of 269,605. Enliven Therapeutics has a twelve month low of $11.67 and a twelve month high of $30.03. The firm has a market cap of $1.03 billion, a P/E ratio of -11.07 and a beta of 1.04. The stock's fifty day moving average price is $21.59 and its two-hundred day moving average price is $23.82.
Insider Buying and Selling at Enliven Therapeutics
In other news, CFO Benjamin Hohl sold 1,000 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $25.04, for a total value of $25,040.00. Following the transaction, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at approximately $325,520. This represents a 7.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Anish Patel sold 6,667 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the sale, the chief operating officer now directly owns 329,977 shares of the company's stock, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,784 shares of company stock valued at $1,092,375 in the last 90 days. 29.20% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Separately, BTIG Research initiated coverage on Enliven Therapeutics in a research report on Friday, December 13th. They set a "buy" rating and a $42.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $38.25.
Get Our Latest Report on ELVN
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Read More

Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.